Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.

Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Del Prete M, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C.

Clin Endocrinol (Oxf). 2013 Jul;79(1):20-6. doi: 10.1111/cen.12108. Epub 2013 Apr 27.

PMID:
23228121
2.

Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.

Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A, Marcocci C.

J Endocrinol Invest. 2012 Jul;35(7):655-60. doi: 10.3275/7970. Epub 2011 Sep 30.

PMID:
21971564
3.

MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.

Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S, Persani L, Beck-Peccoz P, Spada A.

Eur J Endocrinol. 2012 Aug;167(2):157-64. doi: 10.1530/EJE-12-0117. Epub 2012 May 10.

4.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
5.

Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.

Lomonte C, Antonelli M, Losurdo N, Marchio G, Giammaria B, Basile C.

Nephrol Dial Transplant. 2007 Jul;22(7):2056-62. Epub 2007 Apr 20.

PMID:
17449495
6.

Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.

Norman J, Lopez J, Politz D.

Ann Surg Oncol. 2012 May;19(5):1466-71. doi: 10.1245/s10434-011-2065-9. Epub 2011 Sep 16.

PMID:
21922336
7.

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2011 Jan;96(1):E9-18. doi: 10.1210/jc.2010-1221. Epub 2010 Oct 13.

8.

[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].

Arranz Martín A, Azcárate Villalón A, Luque Ramírez M, Santana Durán B, Marazuela Azpíroz M, Paniagua Ruiz A, Carraro R, Gómez Pan A.

Endocrinol Nutr. 2011 Jan;58(1):24-31. doi: 10.1016/j.endonu.2010.09.009. Spanish.

PMID:
21277266
9.

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M.

J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. doi: 10.1210/jc.2008-2640. Epub 2009 May 26.

10.

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Iglesias P, Ais G, González A, Tajada P, García Arévalo C, Fernández Pardo E, Díez JJ.

Am J Med Sci. 2008 Feb;335(2):111-4. doi: 10.1097/MAJ.0b013e3181379f3e.

PMID:
18277118
11.

Cinacalcet for the treatment of primary hyperparathyroidism.

Sajid-Crockett S, Singer FR, Hershman JM.

Metabolism. 2008 Apr;57(4):517-21. doi: 10.1016/j.metabol.2007.11.014.

PMID:
18328354
12.

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M, Payer J, Van De Ven A, Yavropoulou M, Selby P.

Eur J Endocrinol. 2014 Dec;171(6):727-35. doi: 10.1530/EJE-14-0355. Epub 2014 Sep 20.

13.

Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.

Zitt E, Rix M, Ureña Torres P, Fouque D, Jacobson SH, Pétavy F, Dehmel B, Ryba M.

Nephrol Dial Transplant. 2011 Jun;26(6):1956-61. doi: 10.1093/ndt/gfq641. Epub 2010 Oct 14.

PMID:
20947534
14.

Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.

Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.

Nephrol Dial Transplant. 2007 Jun;22(6):1639-44. Epub 2007 Feb 3.

PMID:
17277339
15.

Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.

Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP.

Nephrol Dial Transplant. 2007 Feb;22(2):577-83. Epub 2006 Sep 27.

PMID:
17005527
16.

Cinacalcet for the treatment of primary hyperparathyroidism.

Dillon ML, Frazee LA.

Am J Ther. 2011 Jul;18(4):313-22. doi: 10.1097/MJT.0b013e3181bdc3d0. Review.

PMID:
20228675
17.

The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG.

Nephrol Dial Transplant. 2005 Jul;20(7):1311-4. Epub 2005 Jun 7.

PMID:
15941846
18.

Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.

Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP.

Nephrol Dial Transplant. 2005 Jul;20(7):1315-9. Epub 2005 Jun 7.

PMID:
15941845
19.

Update on the use of cinacalcet in the management of primary hyperparathyroidism.

Marcocci C, Cetani F.

J Endocrinol Invest. 2012 Jan;35(1):90-5. doi: 10.3275/8112. Epub 2011 Nov 21. Review.

PMID:
22104762
20.

Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.

Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M.

Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30.

Supplemental Content

Support Center